HUEY-LING CHEN (陳慧玲)

     ORCID Follow

Research Outline     

Dr. Chen’s research interest centers on cholestatic liver diseases, prevention of hepatitis B virus (HBV) infection and mother-to-infant transmission of HBV (Gastroenterology 2012). The group was the first to characterize Asian patients with progressive familial intrahepatic cholestasis (PFIC), and found Taiwanese patients to have mutations in FIC1, BSEP, or MDR3 genes (J Pediatr 2002, Pediatr Res 2001). The NTUH group also applied rapid diagnostic methods for screening Taiwanese patients with BSEP mutations (J Pediatr 2008) as well as prenatal diagnosis of PFIC. To explore the mechanisms of susceptibility of cholestatic liver disease in newborns and infants, different ontogenic expression and localization of canalicular transporters during human liver development has been found (J Hepatol 2005), as well as different expression of transporters and nuclear receptors in early and late stage biliary atresia (Pediatr Res 2008). Studies also included characterization of neonatal Dubin-Johnson syndrome as caused by MRP2 mutations (Pediatr Res 2006); and clinical and genetic studies on a recently discovered neonatal cholstatic liver disease caused by Citrin deficiency (NICCD)(J Pediatr 2012), as well as vitamin treatment for cholestasis (J Pediatr Gastroenterol Nutr 2012). To explore new therapeutic modalities, she have worked on cell therapies of bsep knockout mice, an animal model for inherited cholestatic liver disease (Hepatology 2009, J Biomed Sci 2008; J Cell Mol Med 2012).